KLTO Overview

Klotho Neurosciences, Inc. operates with two divisions: Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. The Skaergaard Project is located in Southeast Greenland, which is an undeveloped palladium, gold, and platinum deposit. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease). It is engaged in developing and providing new therapies to alleviate and/or reverse the progression of neurodegenerative diseases through the use of cell and gene therapy. It is also focusing on developing therapeutic agents for the treatments for Alzheimer's and Parkinson's disease.

Wall Street analysts forecast KLTO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KLTO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Klotho Neurosciences Inc revenue for the last quarter amounts to -1.85M USD, decreased -35.45

Klotho Neurosciences Inc. EPS for the last quarter amounts to USD, decreased -100.00

Klotho Neurosciences Inc (KLTO) has 3 emplpoyees as of March 22 2026.

Today KLTO has the market capitalization of 0.00 USD.